MARK A SMITH, M.D.
Psychiatric at Washington St, Wilmington, DE
License number
Delaware C1-0007086
Category
Psychiatric
Type
Psychiatry
Address
Address
825 N Washington St, Wilmington, DE 19801
Phone
(302) 655-7110
(302) 655-6185 (Fax)
(302) 655-6185 (Fax)
Organization information
See more information about MARK A SMITH at bizstanding.comMark Smith MD
1601 Concord Pike, Wilmington, DE 19803
Industry:
Psychiatrist
Phone:
(302) 994-4014 (Phone)
Mark Alan Smith
Orlov Counseling & Associate - Mark A Smith MD
Heritage Prosessional Plz, Wilmington, DE 19808
Categories:
Physicians & Surgeons, Psychiatry Physicians
Phone:
(302) 994-4014 (Phone)
Professional information
Imaging Agents And Methods Of Imaging Alpha7-Nicotinic Cholinergic Receptor
US Patent:
2010003, Feb 11, 2010
Filed:
Jan 26, 2009
Appl. No.:
12/321951
Inventors:
Martin G. Pomper - Baltimore MD, US
John L. Musachio - Baltimore MD, US
Hong Fan - Lutherville Timonium MD, US
Robert F. Dannals - Sparks MD, US
Catherine Foss - Baltimore MD, US
Eifion Phillips - Wilmington DE, US
John Gordon - Wilmington DE, US
Dennis McCarthy - Wilmington DE, US
Richard Keith - Wilmington DE, US
Mark Smith - Wilmington DE, US
Richard Heys - Wilmington DE, US
Peter N. Dorff - Wilmington DE, US
John L. Musachio - Baltimore MD, US
Hong Fan - Lutherville Timonium MD, US
Robert F. Dannals - Sparks MD, US
Catherine Foss - Baltimore MD, US
Eifion Phillips - Wilmington DE, US
John Gordon - Wilmington DE, US
Dennis McCarthy - Wilmington DE, US
Richard Keith - Wilmington DE, US
Mark Smith - Wilmington DE, US
Richard Heys - Wilmington DE, US
Peter N. Dorff - Wilmington DE, US
Assignee:
The Johns Hopkins University - Baltimore MD
International Classification:
C07D 453/02, C07D 453/00, A61K 51/04, G01N 33/53
US Classification:
424 189, 546133, 546 83, 424 181, 424 185, 435 72
Abstract:
The present invention relates to radiolabelled compounds particularly 1-azabicyclo[2.2.2]octane compounds (i.e., quinuclidine compounds) which are labeled with one or more radioisotopes and which are suitable for imaging or therapeutic treatment of tissues, organs, or tumors which express the α7-nicotinic cholinergic receptor. In another embodiment, the invention relates to methods of imaging tissues, organs, or tumors using radiolabeled compounds of the invention, particularly tissues, organs, or tumors which express α7-nicotinic cholinergic receptor to which the compounds of the invention have an affinity.
Imaging Agents And Methods Of Imaging Alpha7-Nicotinic Cholinergic Receptor
US Patent:
2005012, Jun 16, 2005
Filed:
Jun 24, 2004
Appl. No.:
10/877813
Inventors:
Martin Pomper - Baltimore MD, US
John Musachio - Baltimore MD, US
Hong Fan - Lutherville Timonium MD, US
Robert Dannals - Sparks MD, US
Catherine Foss - Baltimore MD, US
Eifion Phillips - Wilmington DE, US
John Gordon - Wilmington DE, US
Dennis McCarthy - Wilmington DE, US
Richard Keith - Wilmington DE, US
Mark Smith - Wilmington DE, US
Richard Heys - Wilmington DE, US
Peter Dorff - Wilmington DE, US
John Musachio - Baltimore MD, US
Hong Fan - Lutherville Timonium MD, US
Robert Dannals - Sparks MD, US
Catherine Foss - Baltimore MD, US
Eifion Phillips - Wilmington DE, US
John Gordon - Wilmington DE, US
Dennis McCarthy - Wilmington DE, US
Richard Keith - Wilmington DE, US
Mark Smith - Wilmington DE, US
Richard Heys - Wilmington DE, US
Peter Dorff - Wilmington DE, US
International Classification:
A61K051/00, A61K031/4747, C07D491/14, C07F005/00
US Classification:
424001110, 514278000, 534011000, 546018000
Abstract:
The present invention relates to radiolabelled compounds particularly 1-azabicyclo[2.2.2]octane compounds (i.e., quinuclidine compounds) which are labeled with one or more radioisotopes and which are suitable for imaging or therapeutic treatment of tissues, organs, or tumors which express the a7-nicotinic cholinergic receptor. In another embodiment, the invention relates to methods of imaging tissues, organs, or tumors using radiolabeled compounds of the invention, particularly tissues, organs, or tumors which express a7-nicotinic cholinergic receptor to which the compounds of the invention have an affinity.
Dr. Mark A Smith, New Castle DE - MD (Doctor of Medicine)
Specialties:
Psychiatry
Address:
575 S Dupont Hwy, New Castle 19720
HERITAGE MEDICAL ASSOCIATES
2601 Annand Dr SUITE 7, Wilmington 19808
(302) 994-4014 (Phone), (302) 994-7827 (Fax)
HERITAGE MEDICAL ASSOCIATES
2601 Annand Dr SUITE 7, Wilmington 19808
(302) 994-4014 (Phone), (302) 994-7827 (Fax)
Languages:
English
Education:
Medical School
University of California At San Diego
Graduated: 1984
University of California At San Diego
Graduated: 1984
Mark Alan Smith, Wilmington DE
Specialties:
Psychiatry
Work:
Astrazeneca Pharmaceuticals L.P.
1800 Concord Pike, Wilmington, DE 19803
1800 Concord Pike, Wilmington, DE 19803
Education:
University of California at San Diego (1984)
Method Of Treating Anxious Major Depressive Disorder
US Patent:
2009029, Nov 26, 2009
Filed:
May 19, 2009
Appl. No.:
12/468279
Inventors:
Joseph FREY - Wilmington DE, US
Thomas HUDZIK - Wilmington DE, US
Mark A. SMITH - Wilmington DE, US
Thomas HUDZIK - Wilmington DE, US
Mark A. SMITH - Wilmington DE, US
Assignee:
AstraZeneca AB - Sodertalje
International Classification:
A61K 31/495, A61P 25/24, A61P 25/22
US Classification:
51425504
Abstract:
The invention is directed to using 4-{(3-aminophenyl)[4-(4-fluorobenzyl)piperazin-1-yl]methyl}-N,N-diethylbenzamide, or enantiomer thereof, or pharmaceutically acceptable salt thereof, and/or mixture thereof to treat anxious major depressive disorder (AMDD).
Ligands
US Patent:
2007017, Jul 26, 2007
Filed:
Sep 24, 2004
Appl. No.:
10/573133
Inventors:
Peter Dorff - Wilmington DE, US
John Gordon - Wilmington DE, US
John Heys - Wilmington DE, US
Richard Keith - Wilmington DE, US
Dennis Mccarthy - Wilmington DE, US
Mark Smith - Wilmington DE, US
Eifion Phillips - Bothwyn PA, US
John Gordon - Wilmington DE, US
John Heys - Wilmington DE, US
Richard Keith - Wilmington DE, US
Dennis Mccarthy - Wilmington DE, US
Mark Smith - Wilmington DE, US
Eifion Phillips - Bothwyn PA, US
Assignee:
AstraZeneca AB - Södertälje
International Classification:
A61K 51/00, C07D 471/22
US Classification:
424001110, 546016000
Abstract:
A radioactive compound having the formula: